Investors and Collaborators
The i-Slide and the BiD product lines are leading pre-clinical protein research tools, used by researchers to further enhance their experimental methods and results. These product lines are currently supplied by Inanovate direct to end users, however Inanovate is in discussions with a variety of biochip/device, assay, and diagnostic companies, regarding collaborative / partnership arrangements to leverage established distribution networks, marketing and sales presence, and financial resources.
The i-Screen is scheduled for entry into a Device Master Filing in the summer of 2009, with the first integrated diagnostic test (for prostate cancer), planned for entry into PMA procedures later that year. To support this entry application, Inanovate has in-licensed proprietary auto-antibody biomarkers for prostate cancer.
There are five strategic areas of focus supporting Inanovate’s business model: (i) Operational excellence on substrate production; (ii) Market leadership position in protein biochip substrate performance; (iii) Comprehensive IP protection on core surface technology and associated manufacturing systems; (iv) Control of key downstream IP for selected diagnostic applications; (v) Provision of contract services to industry partners, leveraging Inanovate's leading expertise and facilities.